Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis

被引:0
|
作者
Job F. M. van Boven
Breda Cushen
Imran Sulaiman
Garrett Greene
Elaine MacHale
Matshediso C. Mokoka
Frank Doyle
Richard B. Reilly
Kathleen Bennett
Richard W. Costello
机构
[1] University of Groningen,Department of General Practice & Elderly Care, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)
[2] University of Groningen,Department of Pharmacy, Unit of Pharmacoepidemiology & Pharmacoeconomics
[3] Smurfit Building Beaumont Hospital,Royal College of Surgeons in Ireland, Clinical Research Centre
[4] Royal College of Surgeons in Ireland,Department of Psychology, Division of Population Health Sciences
[5] The University of Dublin,Trinity Centre for Bioengineering, Trinity College
[6] Royal College of Surgeons in Ireland,Division of Population Health Sciences
[7] Royal College of Surgeons in Ireland,Department of Respiratory Medicine
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Four inhaler adherence clusters have been identified using the INCA audio device in COPD patients: (1) regular use/good technique, (2) regular use/frequent technique errors, (3) irregular use/good technique, and (4) irregular use/frequent technique errors. Their relationship with healthcare utilization and mortality was established, but the cost-effectiveness of adherence-enhancing interventions is unknown. In this exploratory study, we aimed to estimate the potential cost-effectiveness of reaching optimal adherence in the three suboptimal adherence clusters, i.e., a theoretical shift of clusters 2, 3, and 4 to cluster 1. Cost-effectiveness was estimated over a 5-year time horizon using the Irish healthcare payer perspective. We used a previously developed COPD health-economic model that was updated with INCA trial data and Irish national economic and epidemiological data. For each cluster, interventions would result in additional quality-adjusted life years gained at reasonable investment. Cost-effectiveness was most favorable in cluster 3, with possible cost savings of €845/annum/person.
引用
收藏
相关论文
共 50 条
  • [41] Cost-effectiveness of a Single-Inhaler Triple Therapy Versus a Dual Bronchodilator for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Australia
    Schroeder, M.
    Shah, D.
    Martin, A.
    Ndirangu, K.
    Risebrough, N.
    Thrasis, A.
    Schembri, S.
    Bremner, P.
    Haberl, M.
    Ismaila, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [42] COST-EFFECTIVENESS ANALYSIS OF UMECLIDINIUM BROMIDE COMPARED TO TIOTROPIUM BROMIDE FOR SYMPTOMATIC PATIENTS WITH COPD IN THE UK
    Ismaila, A.
    Roberts, G.
    Punekar, Y. S.
    O'Leary, M.
    VALUE IN HEALTH, 2014, 17 (07) : A595 - A595
  • [43] COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN SPAIN
    Brosa, M.
    Diaz, S.
    Miravitlles, M.
    Gonzalez-Rojas, N.
    Nieves, D.
    VALUE IN HEALTH, 2009, 12 (07) : A302 - A302
  • [44] COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) IN COPD USING THE IMPACT TRIAL: CHINA MEDICAL INSURANCE SYSTEM PERSPECTIVE
    Wang, X.
    Martin, A.
    Cai, R.
    Tang, Z.
    Bointon, D.
    Noorduyn, S. G.
    Sun, A.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S169 - S169
  • [45] COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) IN COPD USING THE FULFIL TRIAL: CHINA MEDICAL INSURANCE SYSTEM PERSPECTIVE
    Noorduyn, S. G.
    Wang, X.
    Martin, A.
    Cai, R.
    Tang, Z.
    Bointon, D.
    Sun, A.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S70 - S70
  • [46] VALUE OF USING GABAPENTIN FOR KNEE OA PATIENTS: A COST-EFFECTIVENESS ANALYSIS
    Bensen, G. P.
    Rogers, A. C.
    Leifer, V. P.
    Edwards, R. R.
    Neogi, T.
    Kostic, A. M.
    Paltiel, A. D.
    Collins, J. E.
    Hunter, D. J.
    Katz, J. N.
    Losina, E.
    OSTEOARTHRITIS AND CARTILAGE, 2022, 30 : S261 - S262
  • [47] Cost-effectiveness analysis of lifestyle interventions for preventing kidney disease in patients with type 2 diabetes
    Suzuki, Yuta
    Hoshi, Keika
    Shiroiwa, Takeru
    Fukuda, Takashi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2023, 27 (09) : 728 - 736
  • [48] Cost-effectiveness analysis of lifestyle interventions for preventing kidney disease in patients with type 2 diabetes
    Yuta Suzuki
    Keika Hoshi
    Takeru Shiroiwa
    Takashi Fukuda
    Clinical and Experimental Nephrology, 2023, 27 : 728 - 736
  • [49] INFORMING THE PATHWAY OF COPD TREATMENT (THE IMPACT STUDY): SINGLE INHALER TRIPLE THERAPY (FF/UMEC/ VI) VERSUS FF/ VI IN PATIENTS WITH COPD - COST-EFFECTIVENESS IN THE UK
    Martin, A.
    Shah, D.
    Schroeder, M.
    Ndirangu, K.
    Risebrough, N.
    Anley, G.
    Okorogheye, G.
    Fenwick, E.
    Ismaila, A. S.
    THORAX, 2018, 73 : A237 - A237
  • [50] Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review
    Gunda, Resign
    Chimbari, Moses John
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15